Decapeptide-12

A synthetic ten-residue peptide (Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr) identified in a tyrosinase-inhibitor screen and sold from 2009 as the cosmetic brightening ingredient Lumixyl, with human evidence limited to a five-person split-face pilot and small open-label regimen studies.

Also referenced as: Lumixyl, Decapeptide-12 Acetate

COA Public product evidence No certificate records are bound to a tracked Decapeptide-12 product page A record counts here only when a vendor publishes a certificate against one of its own tracked Decapeptide-12 product pages. Other certificates naming this compound may still exist — search the wider certificate database. →

---

What is Decapeptide-12?

Decapeptide-12 is a synthetic linear peptide of ten amino acids with free termini, Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr (YRSRKYSSWY), molecular formula C65H90N18O17, molecular weight about 1,395.5 Da, CAS 137665-91-9. It was identified as “P4” when Basil Hantash’s group at the Elixir Institute of Regenerative Medicine in San Jose, California screened an in-house oligopeptide library for sequences that inhibited tyrosinase, the copper enzyme that controls melanin synthesis, without the melanocyte toxicity that underlies hydroquinone’s effect. The peptide was commercialized by Envy Medical and sold from 2009 as the branded cosmetic ingredient Lumixyl in a 0.01% brightening cream for melasma and other facial hyperpigmentation; it is a cosmetic ingredient, not a drug, and it reaches the research-peptide market as the generic peptide behind that brand.

How it works

• Competitive inhibition of tyrosinase. In the screening paper, P4 inhibited mushroom tyrosinase with a half-maximal inhibitory concentration of 40 micromolar, against 123 micromolar for the related octapeptide P3 and 680 micromolar for hydroquinone in the same assay, which is the origin of the “17-fold more potent than hydroquinone” figure repeated in marketing; kinetic studies showed competitive inhibition, and at 100 micromolar the peptide inhibited human tyrosinase by 25% to 35%, with the degree of inhibition depending on whether L-tyrosine or L-dopa was the substrate (Abu Ubeid et al., Journal of Investigative Dermatology, 2009;129(9):2242-2249).
• Reduced melanin without melanocyte death. Human melanocytes treated with 100 micromolar P4 for seven days contained 43% less melanin (27% for P3), and the authors reported that the reduction was independent of cell proliferation and cytotoxicity, in contrast to hydroquinone, whose depigmenting effect they attributed to melanocyte toxicity rather than tyrosinase inhibition (Abu Ubeid et al., Journal of Investigative Dermatology, 2009). The claimed advantage over hydroquinone is therefore a safety argument from cell culture, not a potency argument from human skin.
• Binding as a substrate analog. Independent work on a Japanese decapeptide, TH10, that shares seven of ten residues with P4 found that P4’s N-terminal and central tyrosines contribute little to inhibition, leaving the C-terminal tyrosine as the active residue, and that docking places the active tyrosine next to the enzyme’s copper ions, consistent with the peptide occupying the substrate site rather than acting allosterically (Ochiai et al., Journal of Bioscience and Bioengineering, 2016;121(6):607-613).
• A delivery problem. The peptide is hydrophilic and, at about 1.4 kDa, large for passive skin permeation. In an in vitro human skin study, the native peptide’s permeation was improved by a microneedle patch but not by oleic acid or menthol, while a palmitoylated analog designed to add lipophilicity showed the best skin retention and responded to the chemical enhancers; docking predicted similar tyrosinase activity for both forms (Chen et al., International Journal of Pharmaceutics, 2021;606:120868). No delivery-enhanced version has been tested in people.

Research status

Decapeptide-12 is a cosmetic ingredient with a small, closely related body of clinical literature. As of November 2026, PubMed indexes seven records that name decapeptide-12 or Lumixyl, plus the 2009 screening paper that calls the molecule P4; the National Library of Medicine carries a supplementary concept record for “Lumixyl,” with decapeptide-12 as an entry term, keyed to the August 2009 pilot. There is no ClinicalTrials.gov registration under any of these names, no investigational new drug application on record, and no head-to-head human comparison with hydroquinone.

The one vehicle-controlled study of the peptide alone. Hantash and Jimenez, Journal of Drugs in Dermatology, 2009;8(8):732-735, enrolled five women with Fitzpatrick phototype IV and moderate melasma that had failed other treatment, and applied 0.01% w/w peptide cream to one side of the face and placebo to the other twice daily for 16 weeks in a double-blind, randomized, split-face design. All five participants showed statistically significant improvement in melasma appearance and overall facial aesthetics on 10-point grading scales, with no visible irritation or allergy. Five participants and investigator-graded scales make this a pilot, and it remains the only published test of the peptide against its own vehicle.

Open-label regimen studies. Every later efficacy study tested the peptide as one component of a multi-product system. Kassim, Hussain and Goldberg, Journal of Cosmetic Laser Therapy, 2012;14(2):117-121, followed 15 women (13 completers) with Fitzpatrick types I to IV and photodamage-related facial hyperpigmentation using the decapeptide-12 cream with an antioxidant cleanser, a glycolic-acid moisturizer and broad-spectrum sunscreen for 24 weeks; 38.5% went from moderate photodamage to clear on the Global Assessment of Photodamage Severity Scale, 46.1% improved by one grade and 15.4% by two. Hantash and Jimenez, Journal of Drugs in Dermatology, 2012;11(5):660-662, is a four-patient case series of the Lumixyl Topical Brightening System (0.01% cream, antioxidant cleanser, 20% glycolic acid lotion and physical sunscreen) in mild-to-moderate melasma, with one patient clearing completely by 6 weeks. The largest study is Ramirez et al., Journal of Drugs in Dermatology, 2013;12(6):e106-e110, an open-label multicenter study in 33 Hispanic women with mild-to-moderate melasma using the same system for 16 weeks: mean Melasma Area and Severity Index scores fell 36%, 46%, 54% and 60% at weeks 4, 8, 12 and 16, with no adverse events. Because 20% glycolic acid and daily sunscreen each reduce melasma scores on their own, none of these studies can attribute the result to the peptide. Bhatia, Hsu and Hantash, Journal of Drugs in Dermatology, 2014;13(1):84-85, is a single-patient report of post-inflammatory hyperpigmentation in skin of color treated with clinic dermalinfusion of a decapeptide-12 solution plus the cream at home, co-authored by the peptide’s inventor.

One sponsor-funded placebo-controlled trial of a combination product. Jiang et al., Journal of Clinical and Aesthetic Dermatology, 2018;11(12):21-25, randomized 28 women with moderate-to-severe melasma, solar lentigines and periocular lines to Trifecting Night Cream 1.0, an Envy Medical product combining decapeptide-12 with encapsulated retinol, bisabolol and bakuchiol, or to a cleanser-and-sunscreen regimen alone, for 24 weeks plus a 4-week regression period; 25 subjects completed (14 active, 11 control) and the active arm outperformed the control on fine lines, lentigines and melasma. The study was funded by Envy Medical, one author was a company director and clinical advisor and another a company employee, and the retinol in the formulation is itself an established treatment for pigmentation, so the peptide’s contribution cannot be isolated.

Independent and review literature. The only independent experimental work is the 2016 Niigata University study of the related decapeptide TH10 (IC50 102 micromolar against the monophenolase reaction), which used P4 as its reference compound and clarified which residues matter. A 2021 review of natural and synthetic tyrosinase-inhibiting peptides covers the P3 and P4 sequences among the synthetic inhibitors (Hariri, Saeedi and Akbarzadeh, Journal of Peptide Science, 2021;27(7):e3329). No academic group outside the originating one has published a human study of the peptide.

Commercial and regulatory footprint. Envy Medical was acquired by Allergan on March 26, 2019, and the Lumixyl line passed into Allergan’s aesthetics portfolio; no regulatory action, recall or discontinuation notice names the ingredient. The ingredient is listed in the EU cosmetic ingredient inventory under the INCI name decapeptide-12 with the functions bleaching and skin conditioning, has no FDA drug approval or marketing application, and has not been the subject of a published Cosmetic Ingredient Review safety assessment as of November 2026.

Common dosage forms

• Topical cream. 0.01% decapeptide-12 cream; also formulated into a night cream with retinol.
• Finished cosmetics. Declared on the ingredient panel as decapeptide-12.
• Research supply. Lyophilized powder or topical solution.

Key considerations

• Regulatory status. The Research Market status reflects that decapeptide-12 has no US drug approval, no marketing application, no registered clinical trial and no compounding pathway. Its clinical development ended with the originating company’s small studies; it is regulated as a cosmetic ingredient and no drug application has been filed.
• A five-person pilot plus uncontrolled regimen studies. One split-face study of five women is the only test of the peptide against its vehicle. The 13-, 4-, 33- and 1-patient studies that followed all combined the peptide with 20% glycolic acid and daily sunscreen, which improve melasma on their own, and the one later placebo-controlled trial tested a retinol-containing cream. Every human study involved the inventor, the manufacturer or both, and no independent group has replicated the clinical findings. The widely repeated claim of superiority to hydroquinone rests on an enzyme-assay comparison of IC50 values; no human study has compared the two.
• Concentration and delivery. The 0.01% creams correspond to roughly 70 micromolar peptide, close to the in vitro IC50 of 40 micromolar, but the only human-skin permeation study found that the native peptide crosses skin poorly without microneedles, and no study has measured how much reaches epidermal melanocytes from a cream.
• Naming confusions. Decapeptide-12 is not oligopeptide-68, a separate transforming-growth-factor-beta-1-biomimetic brightening ingredient from a different supplier that some listings and articles conflate with it; the two have different sequences, different proposed mechanisms and separate INCI entries. It is also distinct from TH10, the Japanese tyrosinase-inhibiting decapeptide that shares seven residues with it, and from unrelated INCI entries such as decapeptide-1, -2, -4 and -22. “P4” is the laboratory designation in the 2009 screening paper; “Lumixyl” is an Envy Medical trademark for the branded formulation.
• Safety signals. Topical use was well tolerated in the published studies, with no irritation or allergy in the five-person pilot and no adverse events in the 33-woman study, and the peptide showed no melanocyte cytotoxicity at 100 micromolar in culture. The absence of signals reflects small, short studies rather than a formal safety evaluation: there are no published sensitization, phototoxicity or long-term data, no Cosmetic Ingredient Review assessment, and no data of any kind on injected or other non-topical exposure.